The Pharmaceutical segment of Johnson & Johnson invested $5.3 billion in 2012 on research & development. The Janssen Pharmaceutical Companies of Johnson & Johnson are dedicated to addressing and solving the most important unmet medical needs of our time, including oncology (e.g., multiple myeloma and prostate cancer), immunology (e.g., rheumatoid arthritis, irritable bowel disease and psoriasis), neuroscience (e.g., schizophrenia, dementia and pain), infectious disease (e.g., HIV/AIDS, Hepatitis C and tuberculosis), and cardiovascular and metabolic diseases (e.g., diabetes). Driven by our commitment to patients, we develop sustainable, integrated healthcare solutions by working side-by-side with healthcare stakeholders, based on partnerships of trust and transparency.
Janssen, The Pharmaceutical Companies of Johnson & Johnson, are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we bring innovative products, services and solutions to people throughout the world. We recognize the impact of serious conditions on people's lives, and we aim to empower people through disease awareness, education and access to quality care. Our research and development strategy focuses on identifying medical needs, and harnessing the best science in the world, whether from our own laboratories, or through strategic relationships and collaborations. We believe transparency of clinical trial data advances science and medicine and is in the best interest of the patients who use our pharmaceutical products and providers who prescribe them.
As one of the Janssen Pharmaceutical Companies, our strategy is to identify the biggest unmet medical needs and match them with the best science, internal or external, to find solutions for patients worldwide. We leverage our world-class discovery and development expertise, and operational excellence, to bring innovative, effective treatments in five therapeutic areas: cardiovascular and metabolism; immunology; infectious diseases and vaccines; neuroscience, and oncology.
Providing medicines for an array of health concerns in several therapeutic areas, including: attention deficit hyperactivity disorder (ADHD), general medicine (acid reflux disease, infectious diseases), mental health (bipolar I disorder, schizophrenia), neurologics (Alzheimer’s disease, epilepsy, migraine prevention and treatment), pain management, and women’s health.
JHI is a newly established team within the Janssen Research & Development, LLC. We are expanding the company’s offerings of healthcare services and solutions by acquiring companies and programs, and establishing partnerships and collaborations both internally and externally. Our goal is to empower healthcare consumers and modernize healthcare delivery
Janssen Diagnostics is committed to saving and improving patients’ lives through the integration and delivery of differentiating diagnostic and health IT solutions into world-class personalized disease management. Building beyond our joint legacy of world-class diagnostic interventions, our mission is to invest and partner in driving revolutionary diagnostic solutions in oncology, infectious diseases, central nervous system diseases, immunologic and cardiovascular disease.
Dedicated to providing physicians with high-value in vitro diagnostic oncology products. Veridex's products may significantly benefit patients through earlier disease detection and may enable personalized strategies to help improve patient management and outcomes